PL425970A1 - Amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, ich zastosowanie medyczne i sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu - Google Patents

Amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, ich zastosowanie medyczne i sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu

Info

Publication number
PL425970A1
PL425970A1 PL425970A PL42597018A PL425970A1 PL 425970 A1 PL425970 A1 PL 425970A1 PL 425970 A PL425970 A PL 425970A PL 42597018 A PL42597018 A PL 42597018A PL 425970 A1 PL425970 A1 PL 425970A1
Authority
PL
Poland
Prior art keywords
triazol
phenyl
phenol
derivatives
amidosulfate
Prior art date
Application number
PL425970A
Other languages
English (en)
Other versions
PL239999B1 (pl
Inventor
Sebastian DEMKOWICZ
Mateusz Daśko
Janusz RACHOŃ
Original Assignee
Politechnika Gdańska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Gdańska filed Critical Politechnika Gdańska
Priority to PL425970A priority Critical patent/PL239999B1/pl
Priority to CA3101768A priority patent/CA3101768C/en
Priority to JP2020570953A priority patent/JP7160387B2/ja
Priority to PCT/PL2018/000080 priority patent/WO2019245393A1/en
Priority to US17/252,703 priority patent/US11939303B2/en
Priority to EP18786433.5A priority patent/EP3790868B1/en
Publication of PL425970A1 publication Critical patent/PL425970A1/pl
Publication of PL239999B1 publication Critical patent/PL239999B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Przedmiotem zgłoszenia są amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu oraz pochodne 4-(1-fenylo-1H-|1,2,3]triazol-4-ylo)-fenolu jako nowe związki. Przedmiotem zgłoszenia jest też pierwsze zastosowanie medyczne amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu oraz pierwsze zastosowanie medyczne pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu. Przedmiotem zgłoszenia jest również zastosowanie nowych związków jako środka o właściwościach inhibitora sulfatazy steroidowej i/lub modulatora receptora estrogenowego. Zgłoszenie obejmuje też zastosowanie nowych związków jako środka przeciwdrobnoustrojowego i/lub modulatora receptora estrogenowego. W szczególności amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu znajdują zastosowanie medyczne jako leki w terapii nowotworowej. Przedmiotem zgłoszenia jest ponadto sposób otrzymywania tych nowych związków, przy czym pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu stanowią produkt pośredni, z którego bezpośrednio otrzymuje się pochodne amidosiarczanowe.
PL425970A 2018-06-18 2018-06-18 A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu PL239999B1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL425970A PL239999B1 (pl) 2018-06-18 2018-06-18 A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu
CA3101768A CA3101768C (en) 2018-06-18 2018-08-20 Sulfamate derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1- phenyl-1h-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
JP2020570953A JP7160387B2 (ja) 2018-06-18 2018-08-20 ４－（１－フェニル－１ｈ－［１，２，３］トリアゾール－４－イル）－フェノールのスルファメート誘導体、４－（１－フェニル－１ｈ－［１，２，３］トリアゾール－４－イル）－フェノールの誘導体、それらの医療用途、および４－（１－フェニル－１ｈ－［１，２，３］トリアゾール－４－イル）－フェニルスルファメート誘導体を得る方法
PCT/PL2018/000080 WO2019245393A1 (en) 2018-06-18 2018-08-20 Sulfamate derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
US17/252,703 US11939303B2 (en) 2018-06-18 2018-08-20 Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
EP18786433.5A EP3790868B1 (en) 2018-06-18 2018-08-20 Sulfamate derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL425970A PL239999B1 (pl) 2018-06-18 2018-06-18 A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu

Publications (2)

Publication Number Publication Date
PL425970A1 true PL425970A1 (pl) 2020-01-02
PL239999B1 PL239999B1 (pl) 2022-02-07

Family

ID=63858012

Family Applications (1)

Application Number Title Priority Date Filing Date
PL425970A PL239999B1 (pl) 2018-06-18 2018-06-18 A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu

Country Status (6)

Country Link
US (1) US11939303B2 (pl)
EP (1) EP3790868B1 (pl)
JP (1) JP7160387B2 (pl)
CA (1) CA3101768C (pl)
PL (1) PL239999B1 (pl)
WO (1) WO2019245393A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939303B2 (en) 2018-06-18 2024-03-26 Politechnika Gdanska Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116589418B (zh) * 2023-04-22 2026-01-23 大连理工大学 一类2-三氮唑乙烷-1-酮/醇类hsp90/hif-1抑制剂及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4320089B2 (ja) * 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
GB0525323D0 (en) * 2005-12-13 2006-01-18 Sterix Ltd Compound
WO2009082398A1 (en) * 2007-12-21 2009-07-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
JP2011530495A (ja) * 2008-08-08 2011-12-22 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体のモジュレーターとして有用な新規のジフェニル１，２，３−トリアゾール誘導体
GB0914767D0 (en) * 2009-08-24 2009-09-30 Sterix Ltd Compound
EP3089969A2 (en) 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
PL239999B1 (pl) 2018-06-18 2022-02-07 Politechnika Gdanska A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939303B2 (en) 2018-06-18 2024-03-26 Politechnika Gdanska Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives

Also Published As

Publication number Publication date
US11939303B2 (en) 2024-03-26
CA3101768A1 (en) 2019-12-26
EP3790868B1 (en) 2023-01-11
PL239999B1 (pl) 2022-02-07
CA3101768C (en) 2023-12-05
WO2019245393A1 (en) 2019-12-26
JP7160387B2 (ja) 2022-10-25
JP2022501310A (ja) 2022-01-06
EP3790868A1 (en) 2021-03-17
US20210188785A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
EP4685160A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MY195500A (en) Vesicles Derived From Lactobacillus Paracasei And Use Of Same
BR112022012110A2 (pt) Compostos e métodos para a degradação direcionada de receptor androgênico
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
SG11201907038WA (en) Quinazoline compound
NZ752250A (en) Compounds, devices, and uses thereof
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
WO2019236775A8 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2018067520A3 (en) Therapeutic agents and methods:
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
BRPI0608815A8 (pt) Composições de anticorpo anti-ctla-4
Zucchini et al. Clinical utility of exemestane in the treatment of breast cancer
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MY209101A (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
ECSP20063690A (es) Anticuerpos
MX2016014408A (es) Emulsion de agua en aceite para el cuidado de la piel.
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
NZ786543A (en) Compounds active towards nuclear receptors
PL425970A1 (pl) Amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, ich zastosowanie medyczne i sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu
PE20200866A1 (es) Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso
EP3760626A4 (en) INNOVATIVE COMPOSITION AND COMPOSITION WITH IT AS AN ACTIVE INGREDIENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
JOP20190040A1 (ar) توليفة من ناهضات fxr